Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24229514 | 0.78 | DGAT1 (0.47) | DGAT1CASP3SENP8SENP7SENP6 | |
| SCHEMBL28893810 | 0.77 | DGAT1 (0.45) | DGAT1CASP3SENP8SENP7SENP6 | |
| SCHEMBL24484640 | 0.77 | DGAT1 (0.47) | DGAT1CASP3SENP8SENP7SENP6 | |
| SCHEMBL9975920 | 0.72 | SNCA (0.36) | SNCA | |
| SCHEMBL10364453 | 0.70 | NTRK1 (0.36) | SNCA | |
| SCHEMBL22967310 | 0.69 | DGAT1 (0.43) | DGAT1SNCA | |
| SCHEMBL31351755 | 0.69 | DGAT1 (0.43) | DGAT1SNCA | |
| SCHEMBL23714049 | 0.69 | DGAT1 (0.40) | DGAT1PDE10A | |
| SCHEMBL25292277 | 0.68 | DGAT1 (0.41) | DGAT1PDE10A | |
| SCHEMBL21465294 | 0.68 | DGAT1 (0.43) | DGAT1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | DGAT1 1536/4885SNCA 1388/4885CASP3 2783/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | DGAT1 1536/4885SNCA 1388/4885CASP3 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.